A randomized, crossover design study of sevelamer carbonate powder and sevelamer hydrochloride tablets in chronic kidney disease patients on haemodialysis

Nephrology Dialysis Transplantation

Volumn 24, Issue 12, 2009, Pages 3794-3799

  Fan, Stanley ^a   Ross, Calum ^b   Mitra, Sandip ^c   Kalra, Philip ^d   Heaton, Jeremy ^e   Hunter, John ^e   Plone, Melissa ^e   Pritchard, Nick ^f  

^a ROYAL LONDON HOSPITAL   (United Kingdom)

^b NORFOLK AND NORWICH UNIVERSITY HOSPITAL   (United Kingdom)

^c MANCHESTER ROYAL INFIRMARY   (United Kingdom)

^d HOPE HOSPITAL   (United Kingdom)

^e GENZYME CORPORATION   (United States)

^f ADDENBROOKE S HOSPITAL   (United Kingdom)

Author keywords

Clinical trial; Haemodialysis patients; Phosphate binder; Powder formulation; Sevelamer carbonate

Indexed keywords

BICARBONATE; CALCIUM; CARBONIC ACID; CHLORIDE; LIPID; PHOSPHORUS; SEVELAMER;

ABDOMINAL DISTENSION; ADULT; ARTICLE; BICARBONATE BLOOD LEVEL; CHRONIC KIDNEY DISEASE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIARRHEA; DRUG FORMULATION; DRUG WITHDRAWAL; DYSPEPSIA; FEMALE; GASTRITIS; HEMODIALYSIS; HUMAN; HYPERPHOSPHATEMIA; MALE; MULTICENTER STUDY; NAUSEA AND VOMITING; PHOSPHATE BLOOD LEVEL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STOMACH DISCOMFORT; TABLET;

ADULT; AGED; AGED, 80 AND OVER; CHELATING AGENTS; CHRONIC DISEASE; CROSS-OVER STUDIES; FEMALE; HUMANS; KIDNEY DISEASES; MALE; MIDDLE AGED; POLYAMINES; POWDERS; PROSPECTIVE STUDIES; RENAL DIALYSIS; TABLETS;

EID: 71049177062     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfp372     Document Type: Article

References (17)

1. Cleary DJ, Matzke GR, Alexander ACM et al. Medication knowledge and compliance among patients receiving long term dialysis. Am J Health Syst Pharm 1995; 52: 1895-1900
2. Claxton AJ, Cramer J, Pierce C. A systematic review of the associations between dose regimens and medication compliance. Clin Ther 2001; 23: 1296-1310
3. Strachan I, Greener M. Medication-related swallowing difficulties may be more common than we realize. Pharm Pract 2005; 411-414
4. Anderson O, Zweidorff O, Hjelde T et al. Problems when swallowing tablets. A questionnaire study from general practice. Tidsskr Nor Laegeforen 1995; 115: 947-949
5. Chertow GM, Burke SK, Lazarus JM et al. Poly[allylamine hydrochlo-ride] (RenaGel): a noncalcemic phosphate binder for the treatment of hyperphosphatemia in chronic renal failure. Am J Kidney Dis 1997; 29: 66-71
6. Goldberg DI, Dillon MA, Slatopolsky EA et al. Effect of RenaGel, a non-absorbed, calcium-and aluminium-free phosphate binder, on serum phosphorus, calcium, and intact parathyroid hormone in end-stage renal disease patients. Nephrol Dial Transplant 1998; 13: 2303-2310
7. Bleyer AJ, Burke SK, Dillon M et al. A comparison of the calcium-free phosphate binder sevelamer hydrochloride with calcium acetate in the treatment of hyperphosphatemia in hemodialysis patients. Am J Kidney Dis 1999; 33: 694-701
8. Chertow GM, Burke SK, Dillon MA et al. Long-term effects of seve-lamer hydrochloride on the calcium x phosphate product and lipid profile of haemodialysis patients. Nephrol Dial Transplant 1999; 14: 2907-2914
9. Chertow GM, Dillon M, Burke SK et al. A randomized trial of sevelamer hydrochloride (RenaGel) with and without supplemental calcium. Strategies for the control of hyperphosphatemia and hy-perparathyroidism in hemodialysis patients. Clin Nephrol 1999; 51: 18-26
10. Slatopolsky EA, Burke SK, Dillon MA. The RenaGel Study Group. RenaGel, a nonabsorbed calcium-and aluminum-free phosphate binder, lowers serum phosphorus and parathyroid hormone. Kidney Int 1999; 55: 299-307
11. Sonikian MA, Pani IT, Iliopoulos AN et al. Metabolic acidosis aggravation and hyperkaliemia in hemodialysis patients treated by seve-lamer hydrochloride. Ren Fail 2005; 27: 143-147
12. DeSanto NG, Frangiosa A, Anastasio P et al. Sevelamer worsens metabolic acidosis in hemodialysis patients. J Nephrol 2006; 19(Suppl 9): S108-S114
13. Delmez J, Block G, Robertson J et al. A randomized, double-blind, crossover design study of sevelamer hydrochloride and sevelamer carbonate in patients on hemodialysis. Clin Nephrol 2007; 68: 386-391
14. Kalantar-Zadeh K, Mehrotra R, Fouque D et al. Metabolic acidosis and malnutrition-inflammation complex syndrome in chronic renal failure. Semin Dial 2004; 17: 455-465
15. Kraut JA. The role of metabolic acidosis in the pathogenesis of renal osteodystrophy. Adv Ren Replace Ther 1995; 2: 40-51
16. Lowrie EG, Lew NL. Death risk in hemodialysis patients: the predictive value of commonly measured variables and an evaluation of death rate differences between facilities. Am J Kidney Dis 1990; 15: 458-482
17. Bommer J, Locatelli F, Satayathum S et al. Association of predialysis serum bicarbonate levels with risk of mortality and hospitalization in the Dialysis Outcomes and Practice Study (DOPPS). Am J Kidney Dis 2004; 44: 661-671 (Pubitemid 39237610)